Michael E Williams

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Acinetobacter Baumannii

Chronic Lymphocytic Leukemia

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Brad S Kahl, Opeyemi A Jagede, Christopher Peterson, Lode J Swinnen, Thomas M Habermann, Stephen J Schuster, Matthias Weiss, Paul A Fishkin, Timothy S Fenske, Michael E Williams
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (7) (2024)
Brad S Kahl, Opeyemi A Jagede, Christopher Peterson, Lode J Swinnen, Thomas M Habermann, Stephen J Schuster, Matthias Weiss, Paul A Fishkin, Timothy S Fenske, Michael E Williams
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Brad S Kahl, Opeyemi A Jagede, Christopher Peterson, Lode J Swinnen, Thomas M Habermann, Stephen J Schuster, Matthias Weiss, Paul A Fishkin, Timothy S Fenske, Michael E Williams
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (7) (2024)
Brad S Kahl, Opeyemi A Jagede, Christopher Peterson, Lode J Swinnen, Thomas M Habermann, Stephen J Schuster, Matthias Weiss, Paul A Fishkin, Timothy S Fenske, Michael E Williams
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (7) (2024)
Brad S Kahl, Opeyemi A Jagede, Christopher Peterson, Lode J Swinnen, Thomas M Habermann, Stephen J Schuster, Matthias Weiss, Paul A Fishkin, Timothy S Fenske, Michael E Williams
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (7) (2024)
Kallesh D Jayappa, Vicki L Gordon, Christopher G Morris, Briana Wilson, B Dharmaveer Shetty, Konrad J Cios, Puja C Arora, Krista M Isaac, Shekhar Saha, Timothy P Bender, Michael E Williams, Craig A Portell, Michael J Weber
Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL. Blood advances 5 (17) (2021)